Factors associated with CD8+ t-cell activation in HIV-1-infected patients on long-term antiretroviral therapy

Lu Zheng, Babafemi Taiwo, Rajesh T. Gandhi, Peter W. Hunt, Ann C. Collier, Charles Williams Flexner, Ronald J. Bosch

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Abnormal levels of CD8+ T-cell activation persist in HIV-1-infected patients on suppressive antiretroviral therapy (ART) and may be deleterious. METHODS: CD8+ T-cell activation (%co-expressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infected patients on ART for ≥96 weeks with concurrent plasma HIV RNA (vRNA) ≤200 copies/mL. Factors associated with CD8+ T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). RESULTS: Participants were 84% male, 47% white, 28% black, 22% Hispanic; with median pre-ART age 38 years and median ART exposure 144 weeks. CD8+ T-cell activation was higher at timepoints when vRNA was 51-200 copies/mL versus ≤50 copies/mL (mean CD8+ T-cell activation 23.4% vs. 19.7%; adjusted difference: 1.7% [95%CI 0.1%-3.4%], p=0.042). Restricting to vRNA≤50 copies/mL, multivariable models showed the following factors associated with higher CD8+ T-cell activation: older age (≥45 vs. ≤30 years: 3.6% [1.4%-5.7%], p=0.004), HCV antibody positivity (3.6% [0.9%-6.2%], p=0.032), Hispanic vs. White (7.2% [5.3%-9.0%], p500 cells/mm: 2.2% [0.7%-3.7%], p

Original languageEnglish (US)
JournalJournal of Acquired Immune Deficiency Syndromes
DOIs
StateAccepted/In press - Jul 26 2014

Fingerprint

HIV-1
T-Lymphocytes
Hispanic Americans
Therapeutics
Implosive Therapy
Hepatitis C Antibodies
HLA-DR Antigens
HIV
RNA

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Factors associated with CD8+ t-cell activation in HIV-1-infected patients on long-term antiretroviral therapy. / Zheng, Lu; Taiwo, Babafemi; Gandhi, Rajesh T.; Hunt, Peter W.; Collier, Ann C.; Flexner, Charles Williams; Bosch, Ronald J.

In: Journal of Acquired Immune Deficiency Syndromes, 26.07.2014.

Research output: Contribution to journalArticle

@article{0384961fd6194323878169c0b4dce671,
title = "Factors associated with CD8+ t-cell activation in HIV-1-infected patients on long-term antiretroviral therapy",
abstract = "BACKGROUND: Abnormal levels of CD8+ T-cell activation persist in HIV-1-infected patients on suppressive antiretroviral therapy (ART) and may be deleterious. METHODS: CD8+ T-cell activation ({\%}co-expressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infected patients on ART for ≥96 weeks with concurrent plasma HIV RNA (vRNA) ≤200 copies/mL. Factors associated with CD8+ T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). RESULTS: Participants were 84{\%} male, 47{\%} white, 28{\%} black, 22{\%} Hispanic; with median pre-ART age 38 years and median ART exposure 144 weeks. CD8+ T-cell activation was higher at timepoints when vRNA was 51-200 copies/mL versus ≤50 copies/mL (mean CD8+ T-cell activation 23.4{\%} vs. 19.7{\%}; adjusted difference: 1.7{\%} [95{\%}CI 0.1{\%}-3.4{\%}], p=0.042). Restricting to vRNA≤50 copies/mL, multivariable models showed the following factors associated with higher CD8+ T-cell activation: older age (≥45 vs. ≤30 years: 3.6{\%} [1.4{\%}-5.7{\%}], p=0.004), HCV antibody positivity (3.6{\%} [0.9{\%}-6.2{\%}], p=0.032), Hispanic vs. White (7.2{\%} [5.3{\%}-9.0{\%}], p500 cells/mm: 2.2{\%} [0.7{\%}-3.7{\%}], p",
author = "Lu Zheng and Babafemi Taiwo and Gandhi, {Rajesh T.} and Hunt, {Peter W.} and Collier, {Ann C.} and Flexner, {Charles Williams} and Bosch, {Ronald J.}",
year = "2014",
month = "7",
day = "26",
doi = "10.1097/QAI.0000000000000286",
language = "English (US)",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Factors associated with CD8+ t-cell activation in HIV-1-infected patients on long-term antiretroviral therapy

AU - Zheng, Lu

AU - Taiwo, Babafemi

AU - Gandhi, Rajesh T.

AU - Hunt, Peter W.

AU - Collier, Ann C.

AU - Flexner, Charles Williams

AU - Bosch, Ronald J.

PY - 2014/7/26

Y1 - 2014/7/26

N2 - BACKGROUND: Abnormal levels of CD8+ T-cell activation persist in HIV-1-infected patients on suppressive antiretroviral therapy (ART) and may be deleterious. METHODS: CD8+ T-cell activation (%co-expressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infected patients on ART for ≥96 weeks with concurrent plasma HIV RNA (vRNA) ≤200 copies/mL. Factors associated with CD8+ T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). RESULTS: Participants were 84% male, 47% white, 28% black, 22% Hispanic; with median pre-ART age 38 years and median ART exposure 144 weeks. CD8+ T-cell activation was higher at timepoints when vRNA was 51-200 copies/mL versus ≤50 copies/mL (mean CD8+ T-cell activation 23.4% vs. 19.7%; adjusted difference: 1.7% [95%CI 0.1%-3.4%], p=0.042). Restricting to vRNA≤50 copies/mL, multivariable models showed the following factors associated with higher CD8+ T-cell activation: older age (≥45 vs. ≤30 years: 3.6% [1.4%-5.7%], p=0.004), HCV antibody positivity (3.6% [0.9%-6.2%], p=0.032), Hispanic vs. White (7.2% [5.3%-9.0%], p500 cells/mm: 2.2% [0.7%-3.7%], p

AB - BACKGROUND: Abnormal levels of CD8+ T-cell activation persist in HIV-1-infected patients on suppressive antiretroviral therapy (ART) and may be deleterious. METHODS: CD8+ T-cell activation (%co-expressing CD38/HLA-DR) was analyzed on blood specimens from 833 HIV-1-infected patients on ART for ≥96 weeks with concurrent plasma HIV RNA (vRNA) ≤200 copies/mL. Factors associated with CD8+ T-cell activation were assessed using generalized estimating equations to incorporate longitudinal measurements (median 4/participant). RESULTS: Participants were 84% male, 47% white, 28% black, 22% Hispanic; with median pre-ART age 38 years and median ART exposure 144 weeks. CD8+ T-cell activation was higher at timepoints when vRNA was 51-200 copies/mL versus ≤50 copies/mL (mean CD8+ T-cell activation 23.4% vs. 19.7%; adjusted difference: 1.7% [95%CI 0.1%-3.4%], p=0.042). Restricting to vRNA≤50 copies/mL, multivariable models showed the following factors associated with higher CD8+ T-cell activation: older age (≥45 vs. ≤30 years: 3.6% [1.4%-5.7%], p=0.004), HCV antibody positivity (3.6% [0.9%-6.2%], p=0.032), Hispanic vs. White (7.2% [5.3%-9.0%], p500 cells/mm: 2.2% [0.7%-3.7%], p

UR - http://www.scopus.com/inward/record.url?scp=84904782907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904782907&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000286

DO - 10.1097/QAI.0000000000000286

M3 - Article

C2 - 25072610

AN - SCOPUS:84904782907

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

ER -